Pancreatic neuroendocrine tumors: Accurate grading with Ki‐67 index on fine‐needle aspiration specimens using the WHO 2010/ENETS criteria by Farrell, Jessica M. et al.
Pancreatic Neuroendocrine Tumors: Accurate Grading
With Ki-67 Index on Fine-Needle Aspiration
Specimens Using the WHO 2010/ENETS Criteria
Jessica M. Farrell, DO1; Judy C. Pang, MD2; Grace E. Kim, MD1; and Z. Laura Tabatabai, MD1
BACKGROUND: The natural history of pancreatic neuroendocrine tumors (panNETs) is extremely variable. One of the
most controversial problems in diagnosis is the accurate prediction of the clinical behavior of these tumors. PanNETs that
behave aggressively with a malignant course may have bland cytologic features, while some tumors with previously
described “malignant” features may behave in a benign or indolent fashion. Various classification schemes have been pro-
posed for grading panNETs. The European Neuroendocrine Tumor Society (ENETS) and 2010 World Health Organization
(WHO) classification schemes include counting the mitotic index and/or the Ki-67 proliferation index for grading. The cur-
rent study was undertaken to determine whether tumors sampled by endoscopic ultrasound-guided fine-needle aspira-
tion (EUS-FNA) can be accurately graded based on the Ki-67 index when compared to surgical samples. METHODS:
Corresponding EUS-FNA cytology and surgical tissue specimens were obtained for 22 tumors and stained for hematoxy-
lin and eosin (H&E) and the Ki-67 proliferation marker (MIB-1 antibody). Samples were graded by scoring Ki-67 staining
indices in accordance with the 2010 ENETS/WHO criteria. The grading scores assigned to the EUS-FNA cytology samples
were compared with the scores assigned to the corresponding histological samples. RESULTS: The majority (86%) of
EUS-FNA cytology samples and corresponding surgical tissue specimens demonstrated concordant grading based on Ki-
67 indices. CONCLUSIONS: These results indicate that EUS-FNA cytology samples can be accurately graded based on
the WHO Ki-67 labeling scheme. Thus, Ki-67 scoring in EUS-FNA cytology samples is an alternative approach for estab-
lishing the grade of panNETs. Accurate grading of panNETs is critical for predicting tumor biology, patient prognosis, and
making informed decisions regarding patient management and treatment. Cancer (Cancer Cytopathol) 2014;122:770-8.
VC 2014 American Cancer Society.
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INTRODUCTION
Pancreatic neuroendocrine tumors (panNETs) are relatively uncommon (accounting for<3% of all pancreatic
neoplasms) and typically occur in adults without a significant gender predilection.1-4 Most tumors occur as soli-
tary, sporadic lesions and a minority are associated with inherited familial syndromes.1,2 PanNETs demonstrate
cytological and morphological heterogeneity and significant variability with respect to clinical outcome. They
are often identified because of symptoms related to the increased secretion of endocrine hormones from tumor
cells. However, up to 40% of panNETs are nonfunctioning tumors and do not secrete measurable levels of hor-
mones, making them difficult to detect and leading to their identification at late stages of disease secondary to
obstruction or abdominal discomfort related to the growing mass.5,6
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The clinical behavior of panNETs has been
described as highly unpredictable, since the morphologic
features do not necessarily reflect clinical outcomes.7,8
The strongest predictors of survival are disease stage and
tumor grade, making early diagnosis extremely impor-
tant.1,9 In general, morphologic examination is performed
to distinguish well-differentiated, low-grade tumors from
poorly differentiated, high-grade tumors.10 Multiple clas-
sification schemes have been proposed for grading pan-
NETs.2,8 The classification system currently
recommended by the World Health Organization
(WHO) is based on the guidelines issued by the European
Neuroendocrine Tumor Society (ENETS). The WHO
classifies panNETs according to tumor histopathology,
proliferative activity, site of origin, invasion, and metasta-
ses. Proliferation is determined by measuring the mitotic
activity and Ki-67 index (Table 1).1,9,11Many studies sug-
gest that the Ki-67 index is related to the malignant poten-
tial and clinical behavior of panNETs and may be an
important prognostic indicator.4,7,8,12
The morphologic features and proliferative indices
of panNETs have been previously evaluated in cytology
studies.3,12 However, these studies were performed before
the current WHO guidelines and one of the studies12 was
performed on cytology smear slides rather than cell block
specimens. The current study was undertaken to deter-
mine whether grading of tumors based on the current
WHO/ENETS recommendations can be accurately per-
formed on cytological cell block samples obtained by
endoscopic ultrasound-guided fine-needle aspiration
(EUS-FNA).
MATERIALS AND METHODS
Institutional Review Board approval was obtained for the
current study. A retrospective review of the institutional
pathology archives over a 13-year period was performed
to identify primary panNETs. A total of 32 cases with
EUS-FNA cytological material were identified. Of those
cases, 25 had correlating surgical specimens available for
evaluation. Formalin-fixed paraffin-embedded cell blocks
from these 25 cases were evaluated to assess for adequacy
of material, arbitrarily set at >100 tumor cells in the cell
block sample. Based on this definition, adequate cell block
samples were available for 22 cases. Representative tissue
blocks of the corresponding surgical specimens were also
obtained. Tissue blocks were selected based on review of
the hematoxylin and eosin (H&E)-stained sections for the
highest mitotic index in comparison with other sections
from the same surgical specimen. Neuroendocrine differ-
entiation was verified by immunohistochemical staining
for the neuroendocrine markers antichromogranin A
(LK2H10, mouse monoclonal; Cell Marque, Rocklin,
Calif) and/or antisynaptophysin (Z66, rabbit polyclonal;
Invitrogen, Carlsbad, Calif) using standard techniques.
Immunohistochemical staining for antitrypsin (mouse
monoclonal; Chemicon International, Temecula, Calif)
was also used in one case to exclude acinar differentiation.
Two unstained slides from each cytological cell
block and each histological surgical tissue block were
obtained for immunohistochemical staining. One slide
from the cytology sample and 1 slide from the surgical his-
tology sample from each case were stained with H&E to
evaluate morphology. The remaining cytology and histol-
ogy slides for each case were stained with MIB-1 antibody
(1:1000 dilution; Dako, Carpinteria, Calif) to assess Ki-
67 proliferation. The mitotic index was calculated on the
H&E sections for the histology samples according to the
2010 WHO guidelines. Ki-67 indices for the cell block
sections were calculated as the total number of tumor cells
with positive nuclear staining divided by the total number
of tumor cells present. Ki-67 indices for histological sec-
tions were calculated as the percentage of tumor cells with
positive nuclear staining in 2000 cells counted in the high-
est area of nuclear labeling as indicated by the WHO/
ENETS guidelines.1 For cases in which there was discord-
ance between the mitotic and Ki-67 grade on histology
samples, the higher grade was assigned according to the
WHO/ENETS recommendations.1
Two pathologists performed all cytological and his-
tological evaluations in a blinded fashion. Cases in which
there were discrepancies between the two pathologists
were evaluated by a third pathologist. Agreement between
cytological grade and histological grade was evaluated
using percent agreement and k-statistics.13
RESULTS
Clinical Characteristics
Clinical characteristics are summarized in Table 2. The
patient population included 9 men and 13 women. The
age at diagnosis ranged from 23 years to 77 years, with a
mean age of 54 years. The localization of tumors varied,
with 41% of tumors located in the pancreatic head, 36%
in the pancreatic tail, and 23% in the pancreatic body.
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Table 1. WHO Neuroendocrine Tumor Classification
WHO 2010 WHO 2004
Grade
Mitoses Per
10 HPFa
Ki-67 Index,
%b Grade Definition
Neuroendocrine tumor,
grade 1
<2 2 Well-differentiated endocrine tumor.
1.1: Benign behavior.
Confined to the pancreas,
<2 cm in diameter, 2
mitoses per 10 HPF, 2%
Ki-67-positive cells, no
angioinvasion or perineural
invasion.
Well-differentiated endocrine tumor.
1.2: Uncertain behavior.
Confined to the pancreas and
1 of the following fea-
tures: 2 cm in diameter, >2
mitoses per 10 HPF, >2%
Ki-67-positive cells,
angioinvasion, perineural
invasion.
Neuroendocrine tumor,
grade 2
2-20 3-20 Well-differentiated endocrine carcinoma.
Low-grade, malignant.
Macroscopic local invasion
and/or metastases.
Neuroendocrine tumor,
grade 3 (NEC)
>20 >20 Poorly differentiated endocrine carcinoma.
High-grade, malignant.
>10 mitoses per 1 HPF.
Abbreviations: HPF, high-power field; NEC, neuroendocrine carcinoma; WHO, World Health Organization.
a HPF is 2 mm2; at least 40 fields are evaluated at 340 magnification in the area of highest mitotic density.
b Percentage of 2000 tumor cells in the area of highest Ki-67 nuclear labeling.
TABLE 2. Clinical Data and Proliferation Indices
Clinical Characteristics
Procedure
Assessment Ki-67 Index
Cytology Histology
Case
No.
Sex/Age,
Years Location
Size,
cm
Functional
Status
Treatment
Modality
Follow-Up,
Months/
Statusa
CP
Present
No. of
Passes
Ki-67,
% Grade
Ki-67,
% Grade
1 Woman/41 Head 2.4 NF R 7/ANR Yes 4 <1 1 <1 1
2 Man/55 Body 4.0 FC R NA Yes 5 <1 1 <1 1
3 Man/77 Tail 1.5 NF R 31/ANR Yes 5 <1 1 <1 1
4 Woman/43 Head 4.6 NF R 169/ANR Yes 4 <1 1 <1 1
5 Woman/62 Body 3.2 NF R 45/ANR Yes 5 <1 1 <1 1
6 Man/60 Body 1.5 NF R 3/ANR Yes 8 <1 1 <1 1
7 Woman/63 Body 2.2 FC R 28/ANR Yes 1 1 1 <1 1
8 Woman/41 Head 1.8 NF R 16/ANR Yes 8 1 1 1 1
9 Man/41 Body 3.3 NF R 3/ANR Yes 7 1 1 1 1
10 Woman/69 Tail 1.8 NF R 28/ANR Yes 5 <1 1 2 1
11 Man/41 Tail 1.6 NF R NA Yes 5 2 1 <1 1
12 Man/63 Head 1.8 FC R 68/ANR Yes 3 2 1 2 1
13 Man/61 Body 1.5 NF R/Chemo 20/ANR Yes 9 1 1 3 2
14 Woman/62 Tail 1.6 NF R 32/ANR Yes 2 4 2 1 1
15 Woman/56 Head 1.8 FC R 7/ANR Yes 3 4 2 4 2
16 Man/23 Head 2.6 NF R 22/ANR Yes 2 3 2 4 2
17 Woman/64 Head 3.0 NF R/Chemo 8/ANR Yes 3 3 2 5 2
18 Woman/53 Body 4.5 FC R/Chemo 12/LM Yes 9 4 2 3 2
19 Woman/62 Tail 8.2 NF R/Chemo 11/ANR Yes 4 8 2 7 2
20 Woman/48 Head 3.0 NF R 8/ANR Yes 7 13 2 13 2
21 Woman/50 Tail 6.0 NF R/Chemo 25/LM and DE Yes 5 3 2 26 3
22 Man/48 Tail 4.8 NA R/Chemo 52/LM Yes 8 36 3 27 3
Abbreviations: ANR, alive with no residual disease; Chemo, chemotherapy; CP, cytopathologist; DE, deceased; FC, functioning; LM, liver metastasis; NA, not
available; NF, nonfunctioning; R, resection.
a From the time of the initial diagnosis on cytology to death or date of last follow-up.
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Tumor functional status was available in 95% the cases
and of those, 76% were nonfunctioning. The overall
tumor size ranged from 1.5 cm to 8.2 cm, with an average
size of 3 cm. Needle size for EUS-FNA sampling ranged
from 19-gauge to 25-gauge; the number of EUS-FNA
passes ranged from 1 to 9 passes. Rapid on-site evaluation
by a cytopathologist was performed in all cases. Treatment
consisted primarily of surgical resection. Approximately
27% of patients were treated with adjuvant chemotherapy
before surgery, the effects of which, in regard to tumor
grading, have to our knowledge not been studied to date.
Patient follow-up ranged from 7 months to 169 months
and the majority of patients were alive without residual
disease at the time of last follow-up. Three patients devel-
oped liver metastases, 2 patients were lost to follow-up,
and 1 patient died of disease.
Mitotic Index
Mitotic grade was found to be discordant with the Ki-67
grade on histological samples in 3 of 22 cases. In all cases,
the mitotic grade was lower than the Ki-67 grade, and
therefore the higher grade was assigned to the tumors
(Table 2).
Ki-67 Index
The percent agreement of grading scores based on Ki-67
proliferation rates between cytological and histological
samples was 86%. The k statistic was 0.74 (95% confi-
dence interval, 49.9-100; P5 .00003), suggesting good
agreement (Table 2).14 Twelve of 22 cases (55%) with Ki-
67 indices 2% were interpreted as grade 1 (Fig. 1). Six
of 22 cases (27%) were scored as grade 2 based on Ki-67
indices ranging from 3% to 20% (Fig. 2). One case was
designated as a grade 3 tumor due to a Ki-67 index>20%
(Fig. 3). Because grade 3 panNETs are rare, an additional
stain for trypsin was performed on the cell block and his-
tological sections of this case to exclude acinar cell differ-
entiation and was found to be negative. Three cases
demonstrated discordance between the cytologic and his-
tologic grades. Case 13 was interpreted as grade 1 based
Figure 1. (A) A grade 1 pancreatic neuroendocrine tumor is shown in a cell block section derived from endoscopic ultrasound-
guided fine-needle aspiration (EUS-FNA) material and (B) the corresponding surgical specimen (H & E stain, original magnifica-
tion 3 400). (C) A cell block section derived from EUS-FNA material and (D) the corresponding surgical specimen are shown
(MIB-1, original magnification 3 400).
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on cell block material but was scored as grade 2 by histo-
logical evaluation. Case 14 was interpreted as grade 2
based on cell block material and grade 1 by histological
evaluation. Finally, case 21 was scored as grade 2 on cyto-
logical examination and grade 3 by histological
evaluation.
DISCUSSION
The results of the current study provide evidence that
WHO grading of panNETs can be performed on cyto-
logic samples by assessing the Ki-67 index on cell block
material and that there is good agreement between the
2010 WHO/ENETS grade obtained through the evalua-
tion of Ki-67 index on EUS-FNA cytology material when
compared with that obtained on surgical resection
specimens.
Several factors have been proposed to be predictors
of malignant potential for panNETs. Regional lymph
node involvement, tumor size>2 cm, and tumor prolifer-
ation rates are among the most important factors found to
be predictive of aggressive tumor behavior.10 A growing
body of evidence suggesting that the proliferation rate is
linked with tumor biological behavior15-17 has led to the
establishment of grading guidelines by the 2010 WHO
and ENETS for panNETs based on mitotic count and the
Ki-67 proliferative index. However, to our knowledge,
the best method to determine tumor grade (ie, mitotic
index vs Ki-67 index) in panNETs remains controversial,
and the recommendations set forth by the WHO/ENETS
schema for the histological evaluation of tumor grade
have not been tested on cytological specimens.
According to the WHO guidelines, the recom-
mended method for determining the mitotic count is to
count 50 high-power fields or a 2 mm2 area and obtain an
average count per 10 high-power fields. This is challenging
in cytological material not only due to the limitations in the
availability of tumor tissue but also because aspiration
Figure 2. (A) A grade 2 pancreatic neuroendocrine tumor is shown in a cell block section derived from endoscopic ultrasound-
guided fine-needle aspiration (EUS-FNA) material and (B) the corresponding surgical specimen (H & E stain, original magnifica-
tion 3 400). (C) A cell block section derived from EUS-FNA material and (D) the corresponding surgical specimen are shown
(MIB-1, original magnification 3 400).
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samples typically represent various regions sampled within a
single tumor. For these reasons, the mitotic index as a mea-
sure of the proliferation rate in small tissue samples is
imprecise and was therefore excluded as a grading method
on the cytological samples in the current study. Grading
according to the mitotic and Ki-67 indices can sometimes
be discordant. In such instances, the recommendation is to
assign the higher grade.1 Studies have shown that tumors
are more often undergraded using the mitotic index com-
pared with the Ki-67 index, as was observed in 14% of the
histology cases in the current study, and that the Ki-67
index correlates significantly and independently with the
clinical outcome of patients with panNETs.8,15,18,19 One
explanation for undergrading by mitotic index may be that
counting mitotic figures is a subjective process and immu-
nostaining allows for the easier and more efficient recogni-
tion and identification of proliferating tumor cells. McCall
et al18 suggested that because the mitotic rate represents the
proliferation per unit area, characteristics such as tumor cell
size or the amount of stroma within a given section may
influence its assessment; because Ki-67 is present in the G1
(Gap 1), G2 (Gap 2), and the S (Synthesis) phase of the
cell cycle in addition to the M (Mitosis) phase, immuno-
staining may demonstrate positivity for Ki-67 when mitoses
are absent.18,19 In their study, greater than one-third of
panNETs designated as grade 1 according to the mitotic
index were upgraded to grade 2 by the Ki-67 index,
whereas only a small minority of tumors designated as
grade 1 according to the Ki-67 index were mitotic grade 2.
The overall survival in the former group was similar to that
of patients with mitotic grade 2 tumors, whereas the latter
group failed to demonstrate any significant clinical or histo-
pathological difference from those patients with mitotic
grade 1 tumors.18
TheWHO/ENETS recommendations for the calcu-
lation of the Ki-67 index is to manually count Ki-67-
positive tumor cells in 2000 tumor cells in the area of
highest nuclear labeling or “hot spot” in tissue sections. In
Figure 3. (A) A grade 3 pancreatic neuroendocrine tumor is shown in a cell block section derived from endoscopic ultrasound-
guided fine-needle aspiration (EUS-FNA) material and (B) the corresponding surgical specimen (H & E stain, original magnifica-
tion 3 400). (C) A cell block section derived from EUS-FNA material and (D) the corresponding surgical specimen are shown
(MIB-1, original magnification 3 400).
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the cell block samples in the current study, we calculated
this index by dividing the number of tumor cells with pos-
itive nuclear staining by the total number of tumor cells
present. Some studies on histological material have con-
sidered an “eyeballed” estimate to be adequate.18 How-
ever, a recent study by Tang et al20 concluded that an
“eyeballed” estimate is not appropriate for assessing the
proliferation index of gastrointestinal and pancreatobili-
ary tract NETs and that digital image analysis and manual
counting are the appropriate methods with which to assess
Ki-67 labeling.20 The loss of architecture and inherent
sampling limitations in cytological material pose chal-
lenges in determining the tumor “hot spot” in cytological
material. Variations in practice settings and expertise
among different operators in evaluating Ki-67 rates and
distinguishing between Ki-67-positive tumor cells and
inflammatory cells present further limitations. Less sub-
jective assessment may be possible with computer-aided
image analysis, such as that proposed by Remes et al,21 in
which surgically resected histological samples of pancre-
atic and ileal NETs were assigned Ki-67-based tumor
grades with the assistance of an image analysis software
program.21
In the current study, three cases demonstrated dis-
cordance between the cytological and histological grades.
Two of these were undergraded and one case was over-
graded based on cytology. Due to tumor heterogeneity in
panNETs, Ki-67 immunoreactivity can be focal, and
EUS-FNA sampling may not be representative of the
most proliferative area within a tumor, leading to under-
grading of the tumor. Conversely, because various regions
of a tumor may be sampled by EUS-FNA, it is possible to
aspirate >1 proliferative “hot spot,” leading to overgrad-
ing of the tumor. Another limitation associated with
EUS-FNA sampling is procedural operator dependence.
Less experienced operators may have difficulty obtaining
a representative cellular sample that can be processed as a
cell block for Ki-67 immunostaining, particularly in the
setting of small tumors or those that have undergone
cystic degeneration.
Results of a study by Larghi et al,22 in which EUS-
FNA cytological samples of nonfunctioning panNETs
stained with MIB-1 to assess the Ki-67 proliferation rate
were used to establish tumor grade, directly support the
results of the current study. In their study, 10 of 12
patients (83%) who underwent subsequent surgical resec-
tion demonstrated concordant preoperative and postoper-
ative tumor grades based on the Ki-67 indices. However,
the details of their analysis and the minimum number of
cells evaluated to obtain a proliferation index on the EUS-
guided samples were not specified. Piani et al showed an
agreement rate of 78% between Ki-67 expression by
immunocytochemistry and immunohistochemistry; how-
ever, the cytological evaluation in their study was per-
formed on cytological smears instead of cell block
material and details regarding smear cellularity and the
number of cells counted were not provided.12 In a study
by Alexiev et al, cytological cell block material obtained
from 15 patients was evaluated for the Ki-67 index using
automated quantitative image analysis software; however,
correlation with surgical material was not performed.15
Small study sample size, particularly for grade 2 and
grade 3 tumors, is a limitation that plagues many studies
involving panNETs. Several reasons may account for this,
among them: 1) high-grade panNETs are rare1,2,17; 2)
patients with high-grade panNETs are treated with chem-
otherapy or placed in drug trials without undergoing sur-
gical resection of the tumors, or the tumors are
unresectable due to patient comorbidities or advanced dis-
ease; 3) of the tumors resected, some are without prior
FNA assessment or the FNA is performed at another facil-
ity before surgical management; and 4) cases for which
FNA material is available may not always have adequate
cell block material for additional evaluation by
immunostaining.
Multiple medical therapies are available for treat-
ment of patients with panNETs. Although localized pan-
NETs are primarily treated with surgical resection,
ablative and embolization techniques are typically used
for the management of liver metastases.23,24 Tumor loca-
tion, grade, stage, and proliferative index play a role in
selecting the appropriate treatment regimens.25 Somato-
statin analogues, chemotherapy, and targeted agents are
the main pharmacological treatments available for
patients with panNETs. Clinical trials evaluating somato-
statin analogues in conjunction with interferon-a for
patients with advanced disease and their application in
grade 1 panNETs is currently ongoing.24-26 Chemother-
apy modalities can be used in patients with unresectable
tumors or as an adjunct therapy for tumor debulking;
however, toxicity limits their use.25,26 Newer agents such
as everolimus and sunitinib can be considered in patients
with advanced grade 2 and grade 3 panNETs that are
refractory to chemotherapy or as an alternative treatment
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to ablative therapy or chemotherapy.24-26 Patients with
localized grade 1 panNETs have also demonstrated
responses to these newer therapies but their usefulness in
patients with low-grade disease is not clearly defined and
such therapies are not recommended if complete surgical
resection can be performed.23,25 Overall, chemotherapy is
not used in patients with resectable grade 1 and grade 2
tumors but can be considered in patients with grade 2 and
grade 3 tumors demonstrating advanced disease.25
The results of the current study demonstrate that
calculation of the Ki-67 proliferation index in cytological
material shows good agreement with that obtained by his-
tological material. Thus, stratification of patients accord-
ing to tumor grade can be done by Ki-67 assessment in
EUS-FNA samples, allowing for more informed decisions
to be made regarding the clinical management of patients.
This is particularly critical for those patients who have
comorbidities that may limit treatment with certain types
of interventions and may serve as a potentially valuable
tool in the preoperative assessment of patients. Larger
studies that include a greater number of patients with
high-grade tumors should be performed to validate and
standardize Ki-67 evaluation in EUS-FNA cytologic sam-
ples as an important strategy for establishing tumor grade
and prognosis in patients with panNETs.
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